Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
- Posted on November 24, 2025
- By CNN
- 1 Views
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said Monday.
